We are monitoring the impact of COVID-19 on MEA Diabetic Retinopathy Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 880
Share on
Share on

Middle East and Africa Diabetic Retinopathy Market Research Report – Segmented By Type of Treatment, Indication, End Users and Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Growth, Trends and Forecasts (2020 to 2025)

Pulished: February, 2020
ID: 880
Pages: 140

The size of the Middle East and Africa Diabetic Retinopathy Market was worth USD 0.7 Billion in 2020 and will reach USD 0.97 Billion by 2025, at a CAGR of 6.86% during the forecast period.

Diabetic retinopathy, the most common diabetic eye disease, occurs when blood vessels in the retina change. Sometimes these vessels close off entirely or even swell and leak fluid. In other cases, abnormal new blood vessels grow on the surface of the retina.

The remarkable rise in the incidence of diabetes in the Middle East and Africa makes the region the fastest developing geographical market during the forecast period. Increasing focus of market players to advance their foothold in the Middle East market, the rapid development of healthcare infrastructure, and growing government and non-government initiatives for emerging consciousness about diabetes management in the general population are a few of the other key factors driving the growth of the MEA diabetic retinopathy market. Other drivers of the diabetic retinopathy market in the Middle East and Africa markets are 

The occurrence of an increase in diabetes in this MEA region is the fastest-growing during the period. Factors that cause the growth in the market are the increasing focus of market players, growing focus on the development of healthcare infrastructure, and also private and public initiatives to create awareness about diabetes management. The growing occurrence of diabetes, lack of diagnosis at the right time and even a non-compliant retinal screening of diabetic patients are likely to promote the demand of this market.

Companies like Bayer AG, Pfizer Inc., Hoffmann-La Roche ltd., Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc. and Ampio Pharmaceuticals Inc. are playing a leading role in the MEA Diabetic Retinopathy Market.

This research report has been segmented and sub-segmented into the following categories:

By Treatment Type:

  • Anti-Vascular Endothelial Growth Factor (VEGF) drug
  • Intraocular Steroid Injection
  • Laser Surgery
  • Vitrectomy     

By Indication:

  • Non-Proliferative Diabetic Retinopathy (NPDR)
    • Mild
    • Moderate
    • Severe
  • Proliferative Diabetic Retinopathy (PDR) 

By End-User:

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

1. Introduction                                                                 

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                           

                1.4 General Study Assumptions                                                

2. Research Methodology                                                                           

                2.1 Introduction                                                              

                2.2 Research Phases                                                      

                                2.2.1 Secondary Research                                            

                                2.2.2 Primary Research                                 

                                2.2.3 Econometric Modelling                                     

                                2.2.4 Expert Validation                                  

                2.3 Analysis Design                                                         

                2.4 Study Timeline                                                          

3. Overview                                                                      

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 New Developments                                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                                      

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                               

5. Market Segmentation                                                                              

                5.1 By Type of Treatment                                                            

                                5.1.1 Anti-Vascular Endothelial Growth Factor (VEGF) drug                                          

                                5.1.2 Intraocular Steroid Injection                                           

                                5.1.3 Laser Surgery                                         

                                5.1.4 Vitrectomy                                             

                5.2 By Indication                                                              

                                5.2.1 Non-Proliferative Diabetic Retinopathy (NPDR)                                      

                                                5.2.1.1 Mild                       

                                                5.2.1.2 Moderate                            

                                                5.2.1.3 Severe                  

                                5.2.2 Proliferative Diabetic Retinopathy (PDR)                                    

                5.3 By End Users                                                             

                                5.3.1 Hospitals                                  

                                5.3.2 Ophthalmic Clinics                                               

                                5.3.3 Ambulatory Surgical Centers                                           

6. Geographical Analysis                                                                              

                6.1 Introduction                                                              

                6.2 Middle-East                                                                

                6.3 Africa                                                            

7. Strategic Analysis                                                                       

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                      

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                               

                                7.2.5 Competitive Rivalry within the Industry                                      

8. Market Leaders' Analysis                                                                        

                8.1 Bayer AG                                                     

                                8.1.1 Overview                                

                                8.1.2 Product Analysis                                   

                                8.1.3 Strategic Evaluation and Operations                                            

                                8.1.4 Financial analysis                                  

                                8.1.5 Legal issues                                            

                                8.1.6 Recent Developments                                       

                                8.1.7 SWOT analysis                                       

                                8.1.8 Analyst View                                          

                8.2 Pfizer Inc.                                                    

                8.3 Hoffmann-La Roche ltd                                                          

                8.4 Regeneron Pharmaceutical Inc.                                                         

                8.5 Novartis AG                                                

                8.6 Valeant Pharmaceutical International Inc.                                                     

                8.7 Abbott Laboratories Inc.                                                       

                8.8 Alimera Science Inc.                                                                

                8.9 Ampio Pharmaceuticals Inc.                                                

9. Competitive Landscape                                                                           

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                        

                9.3 Agreements, collaborations and Joint Ventures                                                          

                9.4 New Product Launches                                                          

10. Expert Opinions                                                                        

                10.1 Market Outlook                                                     

                10.2 Investment Opportunities                                                 

Appendix                                                                           

                a) List of Tables                                                

                b) List of Figures                                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East & Africa Diabetic Retinopathy Market, By Region, From 2020 to 2025 (USD Million)
  2. Middle East & Africa Diabetic Retinopathy Market, By Treatment Type, From 2020 to 2025 (USD Million)
  3. Middle East & Africa Anti-Vascular Endothelial Growth Factor (VEGF) drug Market, By Region, From 2020 to 2025 (USD Million)
  4. Middle East & Africa Intraocular Steroid Injection Market, By Region, From 2020 to 2025 (USD Million)
  5. Middle East & Africa Laser Surgery Market, By Region, From 2020 to 2025 (USD Million)
  6. Middle East & Africa Vitrectomy Market, By Region, From 2020 to 2025 (USD Million)
  7. Middle East & Africa Diabetic Retinopathy Market, By Indication, From 2020 to 2025 (USD Million)
  8. Middle East & Africa Non-Proliferative Diabetic Retinopathy (NPDR) Market, By Region, From 2020 to 2025 (USD Million)
  9. Middle East & Africa Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2020 to 2025 (USD Million)
  10. Middle East & Africa Mild Indication Market, By Region, From 2020 to 2025 (USD Million)
  11. Middle East & Africa Moderate Indication Market, By Region, From 2020 to 2025 (USD Million)
  12. Middle East & Africa Severe Indication Market, By Region, From 2020 to 2025 (USD Million)
  13. Middle East & Africa Proliferative Diabetic Retinopathy (PDR) Market, By Region, From 2020 to 2025 (USD Million)
  14. Middle East & Africa Diabetic Retinopathy Market, By End Users, From 2020 to 2025 (USD Million)
  15. Middle East & Africa Hospitals Market, By Region, From 2020 to 2025 (USD Million)
  16. Middle East & Africa Ophthalmic Clinics Market, By Region, From 2020 to 2025 (USD Million)
  17. Middle East & Africa Ambulatory Surgical Centers Market, By Region, From 2020 to 2025 (USD Million)
  18. Middle East Diabetic Retinopathy Market, By Treatment Type, From 2020 to 2025 (USD Million)
  19. Middle East Diabetic Retinopathy Market, By Indication, From 2020 to 2025 (USD Million)
  20. Middle East Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2020 to 2025 (USD Million)
  21. Middle East Diabetic Retinopathy Market, By End Users, From 2020 to 2025 (USD Million)
  22. Africa Diabetic Retinopathy Market, By Treatment Type, From 2020 to 2025 (USD Million)
  23. Africa Diabetic Retinopathy Market, By Indication, From 2020 to 2025 (USD Million)
  24. Africa Diabetic Retinopathy Market, By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2020 to 2025 (USD Million)
  25. Africa Diabetic Retinopathy Market, By End Users, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample